The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA022208(CLDN19 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: ×200)
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hepg2 and 293T cell, Primary antibody: CSB-PA022208(CLDN19 Antibody) at dilution 1/200 dilution, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期:
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途:
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
基因功能參考文獻:
permeability barriers and affected cell morphology, proliferation, migration, AKT signaling, and gene expression. When claudins are exogenously expressed, ARPE-19 more closely model native RPE. PMID: 27593915
CLDN19 genetic mutation is responsible for familial magnesium deficiency with hypercalciuria and nephrocalcinosis. PMID: 25410674
analysis of a novel mutation c.241C>T in exon 2 of CLDN19 in a Chinese patient PMID: 25555744
Claudin-19, the most abundant claudin in myelin, exhibited no binding to ZO2 protein. PMID: 25712527
patients with CLDN19 mutations have a high risk of progression to chronic renal disease PMID: 23301036
Case Reports: novel CLDN19 mutation in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. PMID: 23538362
The risk of end-stage renal disease in patients with CLDN19 mutations was two times the risk of patients with CLDN16 mutations. Ocular abnormalities were observed only in patients with CLDN19 mutations. PMID: 22422540
In a patient with consanguineous parents, history of disturbed organization and development of the retina, a diagnosis of Familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by claudin-19 mutation should be considered. PMID: 22734304
Ocular manifestations and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that may occur in patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis and may indicate CLDN19 mutations. PMID: 21030577
The identification of CLDN19 mutations in patients with chronic renal failure and severe visual impairment supports the fundamental role of claudin-19 for normal renal tubular function and undisturbed organization and development of the retina. PMID: 17033971